Biomarkers and Antibodies Development for Melanoma

Antibody-based in vitro diagnostic (IVD) tools have proven to be useful in helping clinicians to diagnose or assess the progression of a variety of diseases. As a leading provider of IVD antibody development services, Creative Biolabs has been focusing on the development of high-quality antibodies targeting a wide spectrum of biomarkers specific to different cancer diseases, such as melanoma.

Introduction of Melanoma

Biomarkers and Antibodies Development for Melanoma

Melanoma is a type of cancer that develops from the melanocyte, a melanin-producing cell located in the stratum basale of the epidermis. Melanomas typically occur in the skin, but may rarely occur in the eye, intestines, or mouth. The main known exogenous risk factor for melanoma is exposure to ultraviolet radiation. Meantime, a personal history of sunburn, giant congenital nevi, genetic mutations, and a family history of melanoma all increase the risk of developing melanoma. It has been reported that the incidence of melanoma is increasing continuously worldwide, especially in Australia, New Zealand, and North Europe. Current treatment of melanoma mainly includes surgery, chemotherapy, immunotherapy, and radiation therapy.

Diagnosis of Melanoma

Visual inspection is the most common diagnostic technique for melanoma. A popular method for remembering the signs and symptoms of melanoma is the “ABCDE”, including five critical fundamentals: asymmetry, border, color, diameter, and enlarging. A lesion that is suspected to be melanoma typically has the features like asymmetry, irregular border, and multiple colors. Moles that are greater than 6 mm are more likely to be melanomas than smaller moles, and moles that evolve might be a concern. Although these standard criteria are often used for proper identification of potential melanomas, conditions exist that do not fulfill these criteria but are still cases of melanoma. For instance, many melanomas present as lesions smaller than 6 mm in diameter.

In addition to the “ABCDE”, an important method to aid in the diagnosis of melanotic lesions is dermoscopy. A dermatoscope allows for the magnification of lesions while simultaneously providing a polarized light source rendering the stratum cornea translucent. It has the advantages such as decreasing the number of biopsies of benign skin lesions and providing increased diagnostic accuracy of melanoma.

Immunohistochemistry (ICH) in the Diagnosis of Melanoma

The accurate diagnosis of melanoma is essential for the adequate clinical management of the patients. Besides the histopathologic examination, immunohistochemical studies are often used as an adjunct in distinguishing melanocytic lesions from tumors with different origins or between benign and malignant melanocytic lesions. There have been a number of established markers of melanocytic differentiation, such as the HBM-45 antibodies. It is especially useful in detecting the maturation pattern of the intradermal component of melanocytic lesions and can be a helpful adjunct in distinguishing between nevi and melanomas, including the nevoid variant. The multimarker IHC assay, which incorporates several different markers, has shown a high degree of accuracy of differential diagnosis, suggesting its potential utility to correct or prevent a significant proportion of errors arising from the routine pathological evaluation of melanocytic neoplasms.

With our versatile IVD platform, Creative Biolabs providers high-quality antibody development services from scratch to commercial IVD kits (we can also start with provided antibody candidates). Please feel free to contact us for more information and a formal quote.

Biomarker available now for Melanoma diagnosis:



Online Inquiry

Name:
*Phone:
*E-mail Address:
*Service & Products Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.

Contact Us

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

Follow us on:
Copyright ©2011 - 2019 Creative Biolabs.